
William Jeffery Edenfield MD
Breast Cancer, Hematologic Oncology, Hospice & Palliative, Neuro-Oncology
Medical Director, Institute for Translational Oncology Research Greenville Health System Cancer Institute
Join to View Full Profile
900 W Faris RdGreenville, SC 29605
Phone+1 864-679-3900
Fax+1 864-679-3901
Dr. Edenfield is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Jeff Edenfield, MD, is a hematology/oncology physician and the Executive Medical Director of Oncology for the Prisma Health Cancer Institute in Greenville, South Carolina. He currently serves as medical director for the Institute for Translational Oncology Research, which includes conduct and oversight of phase I and first-in-human clinical trials for new cancer medications as well as management of the biorepository services at Prisma Health Cancer Institute.
Dr. Edenfield received his medical degree from the University of Miami in Florida, and completed his internship, residency and fellowship at Walter Reed Army Medical Center in Washington, DC. He completed a research fellowship in hematologic malignancy at Johns Hopkins University School of Medicine in Baltimore, Maryland. He completed his active-duty service obligation as chief of oncology at Womack Army Medical Center in North Carolina.
Dr. Edenfield is board certified in medical oncology, hematology, internal medicine and hospice and palliative medicine.
Education & Training
National Capital ConsortiumFellowship, Hematology and Medical Oncology, 1995 - 1998
National Capital ConsortiumResidency, Internal Medicine, 1992 - 1995
University of Miami Leonard M. Miller School of MedicineClass of 1992
Certifications & Licensure
SC State Medical License 2003 - 2027
FL State Medical License 1994 - 2005
NC State Medical License 1999 - 2004
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage Stage 2 Certification Orion Health Patient Portal, Orion Health, 2013-2017
- CMS Meaningful Use Stage Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2013-2017
- CMS Meaningful Use Stage Stage 2 Certification MOSAIQ, Elekta - IMPAC Medical Systems, Inc., 2013-2017
Clinical Trials
- A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors Start of enrollment: 2011 Mar 01
- Gemzar, Cisp, Sunitinib Urothelial Ca Start of enrollment: 2008 Aug 01
- Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2011 Mar 01
Publications & Presentations
PubMed
- 1 citationsImpact of frequent ARID1A mutations on protein stability provides insights into cancer pathogenesis.Rajen K Goutam, Gangtong Huang, Exequiel Medina, Feng Ding, William J Edenfield
Scientific Reports. 2025-01-24 - Impact of Frequent ARID1A Mutations on Protein Stability: Insights into Cancer Pathogenesis.Rajen K Goutam, Gangtong Huang, Exequiel Medina, Feng Ding, William J Edenfield
Research Square. 2024-12-19 - 2 citationsPhase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors.Mats Någård, Mei-Lin Ah-See, James Strauss, Trisha Wise-Draper, Howard P Safran
Cancer Chemotherapy and Pharmacology. 2023-09-01
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









